|
US20030091630A1
(en)
*
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US20030152622A1
(en)
*
|
2001-10-25 |
2003-08-14 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral diuretic
|
|
CN100553625C
(zh)
|
2002-04-09 |
2009-10-28 |
弗拉梅技术公司 |
活性成分微囊的口服混悬液
|
|
AU2004204825B2
(en)
|
2003-01-13 |
2007-07-19 |
Dynogen Pharmaceuticals, Inc. |
Method of treating functional bowel disorders
|
|
DE602004029982D1
(de)
*
|
2003-01-30 |
2010-12-23 |
Lek Pharmaceuticals |
Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
|
|
KR20120058618A
(ko)
*
|
2003-01-31 |
2012-06-07 |
다이이찌 산쿄 가부시키가이샤 |
동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
|
|
EP1750717B1
(en)
*
|
2004-02-11 |
2017-07-19 |
Rubicon Research Private Limited |
Controlled release pharmaceutical compositions with improved bioavailability
|
|
US7838552B2
(en)
*
|
2004-06-04 |
2010-11-23 |
Forest Laboratories Holdings Limited |
Compositions comprising nebivolol
|
|
WO2006046528A1
(ja)
*
|
2004-10-29 |
2006-05-04 |
Kowa Co., Ltd. |
糸球体疾患治療剤
|
|
EP1850835A1
(fr)
*
|
2005-02-21 |
2007-11-07 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
|
CN101247832B
(zh)
*
|
2005-06-27 |
2011-12-28 |
第一三共株式会社 |
含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
|
|
DE102005031577A1
(de)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
|
|
PT1919466E
(pt)
|
2005-07-11 |
2012-05-21 |
Cortria Corp |
Formulações para tratamento de anormalidades de lipoproteína compreendendo uma estatina e um derivado de metilnicotinamida
|
|
TWI399223B
(zh)
*
|
2006-09-15 |
2013-06-21 |
Daiichi Sankyo Co Ltd |
奧美沙坦酯及氨氯地平之固體劑型
|
|
KR100888131B1
(ko)
*
|
2006-10-10 |
2009-03-11 |
한올제약주식회사 |
시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
|
|
WO2009084040A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Rubicon Research Private Limited |
Once a day formulation of angiotensin receptor blockers
|
|
JP5607550B2
(ja)
|
2008-03-11 |
2014-10-15 |
ディポメド，インコーポレイティド |
非オピオイド鎮痛剤及びオピオイド鎮痛剤の組合せを含む胃保持性持続放出剤形
|
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
|
US20110117194A1
(en)
*
|
2008-04-29 |
2011-05-19 |
Hanall Biopharma Co., Ltd. |
Pharmaceutical formulation containing angiotensin-ii receptor blocker
|
|
TW201014850A
(en)
|
2008-09-25 |
2010-04-16 |
Takeda Pharmaceutical |
Solid pharmaceutical composition
|
|
DE102008059206A1
(de)
|
2008-11-27 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
|
|
WO2010129686A1
(en)
|
2009-05-05 |
2010-11-11 |
Vapogenix, Inc. |
Novel formulations of volatile anesthetics and methods of use for reducing inflammation
|
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
|
EP2392318A1
(en)
|
2010-05-21 |
2011-12-07 |
Laboratorios Liconsa, S.A. |
A pharmaceutical controlled release composition of losartan
|
|
CN103347517B
(zh)
|
2010-08-11 |
2018-10-02 |
德雷克塞尔大学 |
治疗帕金森病中运动障碍的d3多巴胺受体激动剂
|
|
JP6076913B2
(ja)
|
2010-12-07 |
2017-02-08 |
ドレクセル ユニバーシティ |
癌からの転移を阻害する方法
|
|
US8476221B2
(en)
|
2011-03-18 |
2013-07-02 |
Halimed Pharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders
|
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
KR20190007106A
(ko)
|
2011-12-21 |
2019-01-21 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
ES2612532T3
(es)
|
2012-05-07 |
2017-05-17 |
Bayer Pharma Aktiengesellschaft |
Procedimiento de fabricación de una forma de dosificación farmacéutica que comprende nifedipina y candesartán cilexetilo
|
|
WO2014015157A2
(en)
|
2012-07-19 |
2014-01-23 |
Philadelphia Health & Education Corporation |
Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
|
|
EP3378472A1
(en)
|
2012-08-09 |
2018-09-26 |
Dynamis Therapeutics, Inc. |
Combinations of meglumine
|
|
PT2941233T
(pt)
|
2013-01-07 |
2020-11-13 |
Univ Pennsylvania |
Composições e métodos para tratar linfoma cutâneo de células t
|
|
CA2914365C
(en)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
|
EP3613861A1
(en)
|
2013-07-02 |
2020-02-26 |
EcoPlanet Environmental LLC |
Volatile organic compound formulations having antimicrobial activity
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US20160193155A1
(en)
|
2013-09-02 |
2016-07-07 |
Sun Pharmaceutical Industries Limited |
Pulsatile-release dosage form
|
|
JP6932506B2
(ja)
|
2013-11-26 |
2021-09-08 |
イエール ユニバーシティ |
細胞透過組成物およびそれを用いる方法
|
|
MY176049A
(en)
*
|
2013-12-06 |
2020-07-22 |
Genentech Inc |
Serine/threonine kinase inhibitors
|
|
EP3079692A4
(en)
|
2013-12-09 |
2017-10-18 |
Thomas Jefferson University |
Novel methods of treating a neurodegenerative disease in a mammal in need thereof
|
|
WO2015157262A1
(en)
|
2014-04-07 |
2015-10-15 |
Women & Infants Hospital Of Rhode Island |
Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN106714809A
(zh)
|
2014-08-20 |
2017-05-24 |
耶鲁大学 |
对治疗或预防肝脏疾病或障碍和促进体重减轻有用的新型组合物和方法
|
|
WO2016182968A1
(en)
|
2015-05-08 |
2016-11-17 |
Brown University |
Novel syringolin analogues and methods of making and using same
|
|
JP6995627B2
(ja)
|
2015-05-19 |
2022-02-04 |
イエール ユニバーシティ |
病的石灰化状態を治療するための組成物およびそれを使用する方法
|
|
WO2016201288A1
(en)
|
2015-06-12 |
2016-12-15 |
Brown University |
Novel antibacterial compounds and methods of making and using same
|
|
KR102207539B1
(ko)
|
2015-06-30 |
2021-01-26 |
네우라드 리미티드 |
신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법
|
|
EP3328381A1
(en)
*
|
2015-07-29 |
2018-06-06 |
Takeda GmbH |
Pde4 inhibitor for the treatment of diabetic nephropathy
|
|
WO2017075145A1
(en)
|
2015-10-28 |
2017-05-04 |
Yale University |
Quinoline amides and methods of using same
|
|
JP2018537093A
(ja)
|
2015-11-20 |
2018-12-20 |
イエール ユニバーシティ |
異所性石灰化障害を治療するための組成物およびそれを使用する方法
|
|
US9687475B1
(en)
|
2016-03-24 |
2017-06-27 |
Ezra Pharma Llc |
Extended release pharmaceutical formulations with controlled impurity levels
|
|
US9675585B1
(en)
|
2016-03-24 |
2017-06-13 |
Ezra Pharma |
Extended release pharmaceutical formulations
|
|
EP3448369B1
(en)
|
2016-04-29 |
2025-06-25 |
The Regents of The University of Colorado, A Body Corporate |
Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
|
|
US20210330599A1
(en)
|
2016-08-01 |
2021-10-28 |
University Of Rochester |
Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
|
|
US11390859B2
(en)
|
2016-08-05 |
2022-07-19 |
Yale University |
Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
|
|
AU2017321791B2
(en)
|
2016-09-01 |
2022-03-24 |
Mebias Discovery, Inc. |
Substituted ureas and methods of making and using same
|
|
AU2017353986B2
(en)
|
2016-11-07 |
2021-08-19 |
Arbutus Biopharma Corporation |
Substituted pyridinone-containing tricyclic compounds, and methods using same
|
|
US10941126B2
(en)
|
2017-01-19 |
2021-03-09 |
Temple University-Of The Commonwealth System Of Higher Education |
Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
|
|
EP3601216B1
(en)
|
2017-03-21 |
2023-10-25 |
Arbutus Biopharma Corporation |
Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
|
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|
|
WO2019023621A1
(en)
|
2017-07-28 |
2019-01-31 |
Yale University |
ANTICANCER DRUGS AND METHODS OF MAKING AND USING THEM
|
|
KR20200072478A
(ko)
|
2017-09-08 |
2020-06-22 |
더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 |
Her-구동된 약물-내성암의 치료 또는 예방을 위한 화합물, 조성물 및 방법
|
|
EP3716985A1
(en)
|
2017-11-27 |
2020-10-07 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Compounds, compositions, and methods for treating and/or preventing periodontal disease
|
|
WO2019126214A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
|
|
WO2019126215A1
(en)
|
2017-12-18 |
2019-06-27 |
Tris Pharma, Inc. |
Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
|
|
IL275444B2
(en)
|
2017-12-18 |
2025-01-01 |
Tris Pharma Inc |
Modified release drug powder formulation containing gastric-retaining raft-forming systems with pulsed drug release
|
|
WO2019125184A1
(en)
|
2017-12-19 |
2019-06-27 |
Auckland Uniservices Limited |
Use of biomarker in cancer therapy
|
|
EP3743060A4
(en)
|
2018-01-24 |
2021-11-03 |
The Rockefeller University |
ANTIBACTERIAL COMPOUNDS, RELATED COMPOSITIONS AND THEIR METHODS OF USE
|
|
BR112020024048A2
(pt)
|
2018-05-25 |
2021-02-17 |
Temple University-Of The Commonwealth System Of Higher Education |
composição, e, métodos para descolonizar um organismo microbiano, para destruir ou interromper ou inibir ou reduzir a formação de biofilme de um organismo microbiano e para tratar uma infecção microbiana em um indivíduo.
|
|
US11091473B2
(en)
|
2018-05-29 |
2021-08-17 |
Acadia Pharmaceuticals Inc. |
Compounds for pain treatment, compositions comprising same, and methods of using same
|
|
TWI826492B
(zh)
|
2018-07-27 |
2023-12-21 |
加拿大商愛彼特生物製藥公司 |
經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
|
|
MX2021001877A
(es)
|
2018-08-17 |
2021-07-15 |
Univ Pennsylvania |
Composiciones y métodos para el tratamiento de lesión pulmonar aguda.
|
|
WO2020074944A1
(en)
|
2018-10-11 |
2020-04-16 |
Sanifit Therapeutics S.A. |
Inositol phosphates for the treatment of ectopic calcification
|
|
WO2020081762A1
(en)
|
2018-10-19 |
2020-04-23 |
Temple University-Of The Commonwealth System Of Higher Education |
Tamper-resistant drug dosage forms and methods of making and use thereof
|
|
TW202415643A
(zh)
|
2018-12-12 |
2024-04-16 |
加拿大商愛彼特生物製藥公司 |
經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
|
|
KR20210148078A
(ko)
|
2019-01-30 |
2021-12-07 |
사니핏 테라퓨틱스 에스.에이. |
조직 관류 증가에 사용하기 위한 이노시톨 포스페이트 화합물
|
|
US20200246316A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating post-surgical pain with a thiazoline anti-hyperalgesic agent
|
|
US20200246317A1
(en)
|
2019-02-01 |
2020-08-06 |
Cersci Therapeutics, Inc. |
Methods of treating diabetic neuropathy with a thiazoline anti-hyperalgesic agent
|
|
WO2020227603A1
(en)
|
2019-05-09 |
2020-11-12 |
The Feinstein Institutes For Medical Research |
Hmgb1 antagonist
|
|
JP2022538767A
(ja)
|
2019-06-12 |
2022-09-06 |
ザ ウィスター インスティテュート |
アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
|
|
US11555010B2
(en)
|
2019-07-25 |
2023-01-17 |
Brown University |
Diamide antimicrobial agents
|
|
EP3818983A1
(en)
|
2019-11-11 |
2021-05-12 |
Sanifit Therapeutics S.A. |
Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
|
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
|
BR112022024958A2
(pt)
|
2020-06-09 |
2022-12-27 |
Inozyme Pharma Inc |
Proteínas enpp1 solúveis e usos das mesmas
|
|
EP4015494A1
(en)
|
2020-12-15 |
2022-06-22 |
Sanifit Therapeutics S.A. |
Processes for the preparation of soluble salts of inositol phosphates
|
|
EP4036097A1
(en)
|
2021-01-29 |
2022-08-03 |
Sanifit Therapeutics S.A. |
Ip4-4,6 substituted derivative compounds
|
|
JP2025525092A
(ja)
|
2022-07-29 |
2025-08-01 |
サニフィット・セラピューティクス・ソシエダッド・アノニマ |
異所性石灰化の治療、進行の阻害、および予防に使用するためのｉｐ４－４，６置換誘導体化合物
|
|
TW202412815A
(zh)
|
2022-07-29 |
2024-04-01 |
西班牙商薩尼菲特治療公司 |
Ip5經取代化合物
|
|
KR20250059489A
(ko)
|
2022-09-06 |
2025-05-02 |
하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 |
조현병 및 기타 신경정신장애 및 신경학적 장애의 치료를 위한 환각물질 포함 조합물
|
|
TW202513071A
(zh)
|
2023-08-14 |
2025-04-01 |
以色列商琉璃藥品 (1991) 有限公司 |
Gal475組合物及其使用方法
|
|
WO2025162971A1
(en)
|
2024-01-31 |
2025-08-07 |
Sanifit Therapeutics, S.A. |
Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
|
|
WO2025217094A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Interleukin receptor-associated kinase (irak) protac degraders and medical use thereof
|
|
WO2025217096A1
(en)
|
2024-04-08 |
2025-10-16 |
University Of Rochester |
Inhibitors of leucine-rich repeat kinase 2 (lrrk2) and medical uses thereof
|
|
WO2025217379A1
(en)
|
2024-04-10 |
2025-10-16 |
University Of Rochester |
Drug treatment for macular degeneration
|